Department of Molecular Therapeutics and Drug Discovery, The Scripps Research Institute, 5353 Parkside Drive, Jupiter, FL 33458, USA. lograsso@scripps.edu
Inhibitors of c-jun-N-Terminal Kinase (JNK) have many potential therapeutic indications ranging from neurodegenerative disease, to metabolic disorders, inflammation, cardiovascular disease, and cancer. This overview will highlight biological inhibitors such as JNK-interacting protein (JIP) as well as small molecule inhibitors from various structural classes including, aminopyrimidines and indazoles.